Jun. 4 at 2:33 PM
$IMCR: Immunocore (+1.6%) is a new member of our GROWX rankings this week. IMCR is a commercial-stage biotech company pioneering and delivering immunomodulating medicines. In Q1, Immunocore reported a profit and revenue growth of 33% yr/yr to
$93.9 mln. The stock had been in a multi-month trading range in the
$27-33 area, but recently broke above this range following the Q1 report. We caution that analysts expect a loss in Q2, which would drop it from our rankings. Other additions/deletions from the rankings this week include:
$SLSN $FNGR $TATT
See this week's Top 100 growth stocks here: https://www.briefing.com/todays-free-feature?utm_campaign=freefeature&utm_medium=social&utm_source=x&utm_content=link
#smallcap #midcap #stocks #top100 #growthstocks #StockMarket #EmergingGrowth #TodaysFreeFeature
